论文部分内容阅读
在血吸虫病流行地区,有效的、耐受性好的口服抗血吸虫药物的应用普遍增加。定期应用药物治疗患者常常会出现抗性株,因此药物抗性可能成为血吸虫病的主要问题。作者从巴西和肯尼亚的病人中分离到曼氏血吸虫,并观察小鼠体内该虫体对药物的反应。在巴西分离的不同虫株对吡噻硫酮、羟氨喹和吡喹酮出现明显不同的反应。在肯尼亚用羟氨喹500mg/kg的高剂量,不能将虫全部杀死,在Machakos和Mwea两个流行区的学生治愈率有明显的不同,羟氨喹30mg/kg剂量的治愈率低于在巴西应用20mg/kg的治愈率。在一所学校,治愈率为54%,而重复治疗的病人的治愈率仅为42%。这些结果证实了非洲地区的曼氏血吸虫对羟
In the endemic area of schistosomiasis, there is a general increase in the use of effective, well-tolerated oral anti-schistosome drugs. Drug-resistant patients often develop resistant strains, so drug resistance may be a major problem for schistosomiasis. The authors isolated Schistosoma mansoni from patients in Brazil and Kenya and observed the response of the parasite to the drug in mice. Different strains of insects isolated in Brazil showed markedly different responses to oltipraz, hydroxyquin and praziquantel. In Kenya, high doses of hydroxyquramine 500 mg / kg did not kill all the worms, and there was a clear difference in the cure rates among students in the two endemic areas of Machakos and Mwea where the cure rate was lower with 30 mg / kg hydroxyquine Brazil applies a cure rate of 20 mg / kg. In a school, the cure rate was 54%, while the repeat treatment of patients with a cure rate of only 42%. These results confirm the Schistosoma mansoni to hydroxyl in Africa